CommercialCoverageMedium impact
08.02.50, Chimeric Antigen Receptor Therapy (CART): Carvykti® & Abecma®
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Feb 9, 2026
We identified it
Jun 19, 2026
Summary
A new policy has been established for Chimeric Antigen Receptor Therapy (CART) specifically covering Carvykti® and Abecma® drugs under the pharmacy category. This policy will take effect February 9, 2026, establishing coverage criteria and billing guidelines for these specialized cancer immunotherapy treatments.
Action Required
Before February 9, 2026: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Carvykti® and Abecma® CART therapies. Update billing system and encounter forms if your practice administers these specialized cancer treatments. Oncology providers should be informed of the new policy requirements.